VBI VACCINES INC. (TSE:VBV) Files An 8-K Other Events
Item 8.01 Other Events.
On November 22, 2019, VBI Vaccines Inc. (the “Company”) issued a press release announcing the presentation of early data from Part B of the ongoing Phase 1/2a study of VBI-1901, its cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma patients in a poster presentation at the 24th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
|99.1||Press Release dated November 22, 2019|
VBI Vaccines Inc/BC Exhibit
EX-99.1 2 ex99-1.htm VBI Vaccines Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting ● 33% reduction in tumor size observed in one patient in Part B – reduction sustained through two consecutive MRI scans ● 6-month overall survival (OS) now available for Part A demonstrated benefit for vaccine responders (100%) vs. non-responders (63%) CAMBRIDGE,…
To view the full exhibit click
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).